Mr Marco Gerlinger, Consultant Medical Oncologist
Mr Marco Gerlinger
Consultant Medical Oncologist
Mr Marco Gerlinger
Consultant Medical Oncologist FRCP MD
Mr Gerlinger is a Consultant Medical Oncologist
Areas of expertise
- Anal cancer
- Bowel cancer
- Colon cancer
- Colorectal cancer
- Gastrointestinal cancers
Make an appointment
Address
-
The Harley Street Clinic
35 Weymouth Street, London, W1G 8BJ
-
LOC - Leaders in Oncology Care
95 Harley Street, London, W1G 6AF
-
LOC at Chelsea
102 Sydney Street, Chelsea, London, SW3 6NJ
About Mr Marco Gerlinger
GMC number: 6117372
Year qualified: 2003
Place of primary qualification: Ludwig Maximilian University of Munich
Prof. Marco Gerlinger is a distinguished medical specialist in the treatment of bowel, stomach, and oesophageal cancers. He practices at HCA LOC (Leaders in Oncological Care) and The Harley Street Clinic. Additionally, he serves as a Consultant Medical Oncologist, Chair of Gastrointestinal Cancer Medicine, and the Director of GI Cancer Research at St Bartholomew’s Hospital and Queen Mary University of London.
Prof. Gerlinger’s academic journey began with studying Medicine at the University of Munich, Harvard Medical School, and Imperial College. He earned his research MD from the Institute of Immunology in Munich. His training in General Medicine and Medical Oncology took place in Zurich and London, followed by post-doctoral research training in Zurich and at the CRUK London Research Institute, now known as The Francis Crick Institute.
In 2013, Prof. Gerlinger joined the Royal Marsden Hospital as a consultant in GI cancer and the Institute of Cancer Research as a research team leader. He was appointed to his current roles at St Bartholomew’s Hospital and Queen Mary University London in 2022. Prof. Gerlinger leads a team that conducts clinical trials and develops precision medicine biomarkers and new immunotherapies for both early-stage and advanced or metastatic bowel, stomach, and oesophageal cancers.
Prof. Gerlinger is an active faculty member of the American Society of Clinical Oncology and the European Society of Medical Oncology Annual Meetings 2022. He also contributes to the scientific committees of the American Association of Cancer Research.
Prof. Gerlinger’s expertise and dedication to advancing cancer treatment make him a leading figure in the field of gastrointestinal oncology.
Areas of expertise
- Adenocarcinoma
- Anal cancer
- Biological therapy
- Bowel cancer
- Cancer care
- Cancer genomics
- Chemotherapy
- Clinical trials
- Colon cancer
- Colorectal cancer
- Gastrointestinal cancers
- Genetic testing
- Immunotherapy
- Liver metastases
- Lynch syndrome
- Medical oncology
- Metastases
- Neoadjuvant
- Oesophageal cancer
- Oligometastic disease
- Rectal cancer
- Small bowel cancer
- Stomach (gastric) cancer
- Targeted therapy
Professional memberships
Articles by Mr Marco Gerlinger
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy.
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale.
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine.
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Cancer (r)evolution.
Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.
Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.
